ANIK · Anika Therapeutics, Inc.

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.

Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.

The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.595 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.235 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement.

Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement.

Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement.

Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 15, 2024, the Reporting Person was granted 7,976 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.

Reflects an aggregate of 781 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Reflects an aggregate of 12,104 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

On March 14, 2025, the Reporting Person was granted 3,484 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Reflects an aggregate of 1,449 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 11,324 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

Reflects an aggregate of 5,944 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

Reflects an aggregate of 14,728 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 19,236 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 38,473 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 14, 2025, the Reporting Person was granted 73,559 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 528 shares purchased on May 14, 2025 and 616 shares purchased on November 14, 2025.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

On March 9, 2023, the Reporting Person was granted 60,004 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

Reflects an aggregate of 639 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

The Stock Appreciation Right is payable in cash, shares of common stock, or a combination thereof, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement.

Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.